The newest update to the COVID-19 vaccine reached pharmacies as infections in Indiana began to rise. Members of our audience ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

In July, a High Court judge delivered a mixed ruling in the long-running dispute that has pitted pharmaceutical giant Pfizer ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

BioNTech's shares have experienced a remarkable upswing, with the stock price soaring to $130.90 on NASDAQ, marking a 6.0% increase in the latest session. This surge represents a significant ...

BioNTech SE ADR closed $10.99 short of its 52-week high ($115.99), which the company reached on September 14th.